Ironwood Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Ironwood Pharmaceuticals CEO'su Tom McCourt, Mar2021 tarihinde atandı, in görev süresi 3.75 yıldır. in toplam yıllık tazminatı $ 7.58M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11% maaş ve 89% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.32% ine doğrudan sahiptir ve bu hisseler € 2.19M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 5.7 yıldır.

Anahtar bilgiler

Tom McCourt

İcra Kurulu Başkanı

US$7.6m

Toplam tazminat

CEO maaş yüzdesi	11.0%
CEO görev süresi	3.8yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	5.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Tom McCourt'un ücretlendirmesi Ironwood Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$2m
Jun 30 2024	n/a	n/a	US$9m
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	US$8m	US$834k	-US$1b
Sep 30 2023	n/a	n/a	-US$952m
Jun 30 2023	n/a	n/a	-US$917m
Mar 31 2023	n/a	n/a	US$182m
Dec 31 2022	US$8m	US$805k	US$175m
Sep 30 2022	n/a	n/a	US$168m
Jun 30 2022	n/a	n/a	US$173m
Mar 31 2022	n/a	n/a	US$527m
Dec 31 2021	US$9m	US$732k	US$528m
Sep 30 2021	n/a	n/a	US$530m
Jun 30 2021	n/a	n/a	US$509m
Mar 31 2021	n/a	n/a	US$143m
Dec 31 2020	US$3m	US$576k	US$106m
Sep 30 2020	n/a	n/a	US$111m
Jun 30 2020	n/a	n/a	US$97m
Mar 31 2020	n/a	n/a	US$84m
Dec 31 2019	US$5m	US$511k	US$59m
Sep 30 2019	n/a	n/a	US$19m
Jun 30 2019	n/a	n/a	-US$153m
Mar 31 2019	n/a	n/a	-US$173m
Dec 31 2018	US$2m	US$465k	-US$194m
Sep 30 2018	n/a	n/a	-US$190m
Jun 30 2018	n/a	n/a	-US$71m
Mar 31 2018	n/a	n/a	-US$108m
Dec 31 2017	US$2m	US$450k	-US$55m

Tazminat ve Piyasa: Tom 'nin toplam tazminatı ($USD 7.58M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Tom 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Tom McCourt (67 yo)

3.8yrs

Görev süresi

US$7,583,270

Tazminat

Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 08, 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since Jun...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas McCourt	CEO, Principal Financial Officer & Director	3.8yrs	US$7.58m	0.32% € 2.2m
John Minardo	Senior VP	3.3yrs	US$2.44m	0.079% € 543.9k
Michael Shetzline	Chief Medical Officer	5.9yrs	US$2.60m	0.16% € 1.1m
Ronald Silver	Corporate Controller & Principal Accounting Officer	5.7yrs	Veri yok	0.042% € 290.5k
Rosario Lobrutto	VP & Global Head of Technical Operations	less than a year	Veri yok	Veri yok
Greg Martini	Vice President of Strategic Finance & Investor Relations	no data	Veri yok	Veri yok
Beth Calitri	VP of Corporate Communications & Media Relations	2.9yrs	Veri yok	Veri yok
Mike Nanfito	Vice President of Sales & Sales Excellence	3.3yrs	Veri yok	Veri yok
Susanna Huh	VP & Head of Clinical Development	2.3yrs	Veri yok	Veri yok
Matt Roache	Director of Investor Relations	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: I76 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas McCourt	CEO, Principal Financial Officer & Director	3.5yrs	US$7.58m	0.32% € 2.2m
Jay Shepard	Independent Director	4yrs	US$300.71k	0.079% € 541.1k
Perry Halushka	Member of Pharmaceuticals Advisory Committee	no data	Veri yok	Veri yok
Alexander Denner	Independent Director	4.1yrs	US$300.69k	0.098% € 668.5k
Mark Currie	Independent Director	5.7yrs	US$300.71k	0.36% € 2.4m
Andrew Dreyfus	Independent Director	8.7yrs	US$310.71k	0.12% € 804.9k
Michael Mendelsohn	Member of Pharmaceutical Advisory Committee	7.8yrs	Veri yok	Veri yok
Catherine Moukheibir	Independent Director	5.7yrs	US$310.69k	0.046% € 311.9k
Julie McHugh	Independent Chairman of the Board	10.8yrs	US$335.71k	0.10% € 700.6k
Marla Kessler	Independent Director	5.7yrs	US$300.71k	0.076% € 516.9k
Jon Duane	Independent Director	5.7yrs	US$305.71k	0.091% € 621.5k

5.7yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: I76 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 23:46
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Ironwood Pharmaceuticals, Inc. 37 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Raghuram Selvaraju	Aegis Capital Corporation
Geoffrey Meacham	Barclays
Patrick Trucchio	Berenberg

Ironwood Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Independent Director recently sold €479k worth of stock

CEO & Director recently sold €402k worth of stock

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Senior VP recently bought €281k worth of stock

CEO & Director recently sold €337k worth of stock

Recent updates

Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.098 in 3Q 2023)

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 31%

New minor risk - Shareholder dilution

New minor risk - Financial position

Second quarter 2024 earnings released: US$0.005 loss per share (vs US$6.84 loss in 2Q 2023)

Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for Its Fiscal Year 2024

New major risk - Share price stability

Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Growth-Defensive Index

Insufficient new directors

Independent Director recently sold €479k worth of stock

CEO & Director recently sold €402k worth of stock

Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024

First quarter 2024 earnings released: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023)

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

New minor risk - Insider selling

Full year 2023 earnings released: US$6.45 loss per share (vs US$1.13 profit in FY 2022)

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024

Ironwood Pharmaceuticals, Inc. provides Earnings Guidance for the Year 2023

Ironwood Pharmaceuticals, Inc. Provids Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.10 (vs US$0.33 in 3Q 2022)

Ironwood Pharmaceuticals, Inc. Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. Presents Positive Final Data from Stars Nutrition, A Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Senior VP recently bought €281k worth of stock

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$6.84 loss per share (vs US$0.24 profit in 2Q 2022)

Ironwood Pharmaceuticals, Inc. Revises Financial Guidance for the Year 2023

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

CEO & Director recently sold €337k worth of stock

Ironwood Pharmaceuticals, Inc. Presents Results from Phase III Clinical Trial in Pediatric Patients

First quarter 2023 earnings released: EPS: US$0.30 (vs US$0.25 in 1Q 2022)

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

Senior VP & COO recently sold €366k worth of stock

Full year 2022 earnings released: EPS: US$1.13 (vs US$3.26 in FY 2021)

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for 2023

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

Senior VP & COO recently sold €314k worth of stock

Senior VP recently sold €74k worth of stock

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.34 in 3Q 2021)

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of Linzess® (Linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

Senior VP & COO recently sold €335k worth of stock

Second quarter 2022 earnings released: EPS: US$0.24 (vs US$2.42 in 2Q 2021)

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2022

High number of new directors

Ironwood Pharmaceuticals, Inc. to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

First quarter 2022 earnings released: EPS: US$0.25 (vs US$0.25 in 1Q 2021)

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022

High number of new directors

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022

Executive Chairman of the Board recently sold €98k worth of stock

Third quarter 2021 earnings released: EPS US$0.34 (vs US$0.21 in 3Q 2020)

Ironwood Pharmaceuticals Announces FDA Approval of Revised Linzess® (Linaclotide) Label

Second quarter 2021 earnings released: EPS US$2.42 (vs US$0.16 in 2Q 2020)

Principal Accounting Officer, CFO, Senior VP & Treasurer Gina Consylman has left the company

Ironwood Pharmaceuticals Announces The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$0.25 (vs US$0.021 in 1Q 2020)

CEO & Director Mark Mallon has left the company